Healthcare professionals’ implementation of EBP lagging
Although healthcare professionals’ self‐reported evidence-based practice (EBP) knowledge, skills, attitudes, and beliefs are at a moderate to high level, this doesn’t translate into EBP…
Web Exclusives
Prescription drugs in pregnant and nursing women
On May 8, the FDA released two draft guidance documents designed to improve understanding of effects of prescription drugs in pregnant and nursing women.…
FDA approves treatment for two rare diseases
On May 6, the FDA approved Ruzurgi (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome in patients 6 to less than 17 years…
Healthcare professionals and medicinal cannabis
According to a systematic review in PLOSOne, healthcare professionals generally support the use of medicinal cannabis, but they lack knowledge and are concerned about…
ANA on the Frontline, May 2019
Learn about the top issues facing ANA member nurses, how ANA is working for you, and what ANA is doing to advance nursing. In…
May 2019 Vol. 14 No. 5
This issue includes two articles with so much information that we had to break them into two parts. The first is a feature titled…
FDA approves first treatment for pediatric patients with lupus
On April 26, the FDA approved Benlysta (belimumab) I.V. infusion for treatment of children with systemic lupus erythematosus (SLE). This is the first FDA-approved…
FDA approves treatment for hepatitis C in children
On April 30, the FDA approved Mavyret (glecaprevir and pibrentasvir) tablets to treat all six genotypes of hepatitis C virus (HCV) in children ages…
FDA approves medical device for ADHD
On April 19, the FDA permitted marking of the first medical device to treat attention deficit hyperactivity disorder (ADHD): Monarch external Trigeminal Nerve Stimulation…
FDA approves generic naloxone nasal spray
On April 19, the FDA approved the first generic naloxone hydrochloride nasal spray (Narcan). (more…)
Global resurgence of measles
It’s not just the United States that’s experiencing a resurgence of measles. Experts writing in the New England Journal of Medicine note that the…
FDA approves first targeted therapy for bladder cancer
On April 12, the FDA approved Balversa (erdafitinib) for adult patients with locally advanced or metastatic bladder cancer that has a susceptible genetic alteration…
Healthcare professionals’ implementation of EBP lagging
Although healthcare professionals’ self‐reported evidence-based practice (EBP) knowledge, skills, attitudes, and beliefs are at a moderate to high level, this doesn’t translate…
Prescription drugs in pregnant and nursing women
On May 8, the FDA released two draft guidance documents designed to improve understanding of effects of prescription drugs in pregnant and…
FDA approves treatment for two rare diseases
On May 6, the FDA approved Ruzurgi (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome in patients 6 to less than…
Healthcare professionals and medicinal cannabis
According to a systematic review in PLOSOne, healthcare professionals generally support the use of medicinal cannabis, but they lack knowledge and are…
ANA on the Frontline, May 2019
Learn about the top issues facing ANA member nurses, how ANA is working for you, and what ANA is doing to advance…
May 2019 Vol. 14 No. 5
This issue includes two articles with so much information that we had to break them into two parts. The first is a…
FDA approves first treatment for pediatric patients with lupus
On April 26, the FDA approved Benlysta (belimumab) I.V. infusion for treatment of children with systemic lupus erythematosus (SLE). This is the…
FDA approves treatment for hepatitis C in children
On April 30, the FDA approved Mavyret (glecaprevir and pibrentasvir) tablets to treat all six genotypes of hepatitis C virus (HCV) in…
FDA approves medical device for ADHD
On April 19, the FDA permitted marking of the first medical device to treat attention deficit hyperactivity disorder (ADHD): Monarch external Trigeminal…
FDA approves generic naloxone nasal spray
On April 19, the FDA approved the first generic naloxone hydrochloride nasal spray (Narcan). (more…)
Global resurgence of measles
It’s not just the United States that’s experiencing a resurgence of measles. Experts writing in the New England Journal of Medicine note…
FDA approves first targeted therapy for bladder cancer
On April 12, the FDA approved Balversa (erdafitinib) for adult patients with locally advanced or metastatic bladder cancer that has a susceptible…
Test Your Knowledge
Cannabis TYK
Get your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.NurseLine Newsletter
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.